Premature Labor (Tocolysis) - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Premature Labor (Tocolysis) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H2 2015', provides an overview of the Premature Labor (Tocolysis) 's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) 
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Premature Labor (Tocolysis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premature Labor (Tocolysis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis) 
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Premature Labor (Tocolysis) Overview 7
Therapeutics Development 8
Pipeline Products for Premature Labor (Tocolysis) - Overview 8
Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis 9
Premature Labor (Tocolysis) - Therapeutics under Development by Companies 10
Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes 11
Premature Labor (Tocolysis) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Premature Labor (Tocolysis) - Products under Development by Companies 15
Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes 16
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development 17
Allergan Plc 17
GlaxoSmithKline Plc 18
Kissei Pharmaceutical Co., Ltd. 19
Lipocine Inc. 20
ObsEva SA 21
Premature Labor (Tocolysis) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AT-814 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
bedoradrine sulfate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
hydroxyprogesterone caproate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OBE-001 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OBE-002 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Progesterone Second Generation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
retosiban - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules for Premature Labor - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Premature Labor (Tocolysis) - Recent Pipeline Updates 41
Premature Labor (Tocolysis) - Dormant Projects 45
Premature Labor (Tocolysis) - Dormant Projects 45
Premature Labor (Tocolysis) - Discontinued Products 46
Premature Labor (Tocolysis) - Product Development Milestones 47
Featured News & Press Releases 47
Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study - Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women 47
Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour 47
Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour 48
Feb 27, 2012: Watson Receives Complete Response Letter From FDA For Progesterone Vaginal Gel 8% 48
Feb 09, 2012: Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories 49
Jan 20, 2012: FDA Advisory Committee Declines To Recommend Approval Of Watson's Progesterone Vaginal Gel 8% For Reduction Of Risk Of Preterm Birth In Women With Short Uterine Cervical Length 49
Nov 10, 2011: Columbia Laboratories And Watson Pharmaceuticals Confirm FDA Advisory Committee To Review Preterm Birth NDA 50
Jun 27, 2011: Columbia Laboratories' NDA For PROCHIEVE Vaginal Progesterone Gel Accepted For Filing By FDA 51
Apr 26, 2011: Columbia Laboratories Submits NDA For PROCHIEVE Vaginal Progesterone Gel 51
Apr 06, 2011: Columbia And Watson Announce Publication Of Positive Phase III PROCHIEVE Vaginal Progesterone Gel Study Results 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), H2 2015 8
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Premature Labor (Tocolysis) - Pipeline by Allergan Plc, H2 2015 17
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2015 18
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 19
Premature Labor (Tocolysis) - Pipeline by Lipocine Inc., H2 2015 20
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 24
Number of Products by Stage and Mechanism of Action, H2 2015 26
Number of Products by Stage and Route of Administration, H2 2015 28
Number of Products by Stage and Molecule Type, H2 2015 30
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H2 2015 41
Premature Labor (Tocolysis) - Dormant Projects, H2 2015 45
Premature Labor (Tocolysis) - Discontinued Products, H2 2015 46